Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here to find out why GERN stock is a Buy.
The Martin Jädersten group is investigating biological and clinical aspects of acute myeloid leukemia (AML) and runs academic trials exploring novel treatment strategies. The team leader Martin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback